The randomized, double-blind, placebo-controlled study was conducted in cooperation with the Luigi Sacco Hospital in Milan, Italy and the University of Milan. ”This new clinical study is part of Chr. Hansen’s comprehensive clinical study program,” says Chr. Hansen’s Birgit Michelsen, Director of Scientific Affairs, Health & Nutrition Division. “The outcomes of this study, as well as data from previous studies on BB-12® and L. casei 431®, show that supplementation with these probiotic strains result in a strengthening of various parts of the immune system. This will very likely translate into a clinical benefit, such as reduced rates of infection”.
In the study, 211 healthy adults were divided into two probiotic groups (receiving BB-12® and L. casei 431®, respectively) and two placebo groups. The number of persons experiencing a substantial increase in flu antibodies was significantly greater in both probiotic groups than in the placebo groups. For example, in the BB-12® group 66% had a substantial increase in the specific antibody 'IgG3' compared to only 4% in the placebo group. Likewise, in the L. casei 431® group 46% had a substantial increase compared to just 2% in the placebo group.
“Food manufacturers as well as dietary supplements producers observe an increasing consumer interest in probiotics with credible, scientifically documented health benefits,” comments Lars Bredmose, Marketing Director, Probiotic Cultures, Chr. Hansen. “This study further strengthens Chr. Hansen’s probiotic portfolio of strains with documented health benefits”.
Lars Bredmose continues: “We are already successfully marketing powerful food and dietary supplements solutions, which contain BB-12® and L. casei 431®, for consumer products supporting the immune system: probiotic yoghurt blends, chewable tablets, powder sticks, and capsules. We expect this study to further inspire international players in the food and supplements industries to launch probiotic products with evident health benefits.”
Read the study article called “Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model; a randomised, double-blind, placebo-controlled study” here:http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=8369014
For further information on this press release, please contact:
Ulrik Raabjerg Soendergaard, Communications Consultant, Corporate Communications
Telephone: +45 45 74 71 09
About Chr. Hansen
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food,
nutritional, pharmaceutical and agricultural industries. All solutions are based on strong research and
development competencies and significant technology investments. Revenue in FY2009/10 was EUR 576
million. The company enjoys market leadership in all its divisions: Cultures & Enzymes, Health & Nutrition
and Natural Colors. There are more than 2,300 dedicated employees in over 30 countries. Chr. Hansen is
listed on the NASDAQ OMX stock exchange in <place w:st="on"><city w:st="on">Copenhagen</city>, <country-region w:st="on">Denmark</country-region></place>. For further information, please visit www.chr-hansen.com.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.